Biolife solutions stock.
The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.
BioLife Sciences is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. 2831 Saint Rose Parkway Suite 200 Henderson, NV 89052 United StatesAug 9, 2021 · BOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton ... BOTHELL, Wash., Nov. 4, 2021 / PRNewswire / -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.BioLife Solutions, Inc. reaffirmed 2023 revenue guidance for the fiscal 2023. For the period, the company expects revenue to range from $188 million to $202 million, reflecting year-over-year growth...
The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.
Shares of BioLife Solutions ( BLFS 7.11%) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company's ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Rhumbline Advisers decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 8.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 80,251 shares of the medical equipment provider’s stock after selling 7,097 shares during the period. Rhumbline Advisers’ holdings in BioLife Solutions were worth $1,774,000 as of its most recent […]Dec 4, 2023 · Biolife Solutions Inc (NASDAQ:BLFS) has a beta value of 1.60 and has seen 2.24 million shares traded in the last trading session. The company, currently valued at $596.91M, closed the last trade at $13.25 per share which meant it gained $0.88 on the day or 7.11% during that session. The BLFS stock ... BOTHELL, Wash., July 7, 2020 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price ...If you’re looking to donate plasma, Biolife Plasma Centers are a fantastic option. They offer convenient locations, a streamlined donation process, and compensation for your time. In this comprehensive guide, we’ll cover everything you need...Biolife Solutions stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Biolife ...
Sep 1, 2021 · BOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ...
Nov 9, 2022 · BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago ...
Aug. 9, 2021, 08:06 AM. INDIANAPOLIS, Aug. 9, 2021 /PRNewswire/ -- Sexton Biotechnologies, a provider of novel manufacturing solutions for the cell and gene therapy (CGT) industry, today announced ...The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.BioT™ ULT Transporter maintains samples at -50°C for 24 hours. BioT LN2 Transporter maintains cryogenic temperature at -150°C for approximately 2 hours. Ready to use in approximately 10 minutes. Lightweight, easy to …The corporate mailing address for Ms. Aebersold and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Sarah Aebersold's contact information.Aug 9, 2023 · What happened. Shares of BioLife Solutions ( BLFS 3.76%) were down by more than 27% as of 1:15 p.m. on Wednesday after the healthcare company posted its second-quarter earnings report. The stock ...
Nov 9, 2022 · BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago ... Aug 9, 2021 · BOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton ... BOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ...Chief Quality Officer Of Biolife Solutions Trades $760K In Company Stock. (Benzinga) Sep-20-21 08:00AM. BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors. (PR Newswire) BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings ...BioLife Solutions Inc (ISIN: US09062W2044, WKN: A1XCF2): ✓ Precio Acciones BioLife Solutions Inc ✓ Rendimiento de Dividendos y Fechas, ✓ News ✓ Plan de ...Webull offers BioLife Solutions Inc stock information, including NASDAQ: BLFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLFS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for …Chief Quality Officer Of Biolife Solutions Trades $760K In Company Stock. (Benzinga) Sep-20-21 08:00AM. BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors. (PR Newswire) BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings ...
Get the latest BioLife Solutions, Inc. (BLFS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the company's performance outlook, earnings date, dividend and yield, fair value, ratings and more. Our Isothermal LN2 freezers are available with optional SenseAnywhere technology, which combines wireless sensors and secure cloud storage, to easily monitor and track the Isothermal freezer performance from anywhere 24/7. Our isothermal cryogenic freezers are designed with a completely dry storage area and deliver unmatched temperature uniformity.
BLFE | Complete BioLife Sciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.The BioLife Solutions stock price fell by -1.88% on the last day (Wednesday, 29th Nov 2023) from $12.75 to $12.51.It has now fallen 3 days in a row. During the last trading day the stock fluctuated 9.31% from a day low at $12.46 to a day high of $13.62.The price has been going up and down for this period, and there has been a …Stock CONTACT BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 NAVIGATION Investors Knowledge Center Company …With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted Net Income per share basis (Non-GAAP) in ...The current BioLife Solutions [ BLFS] share price is $13.57. The Score for BLFS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. BLFS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.In today’s fast-paced world, personal health tracking has become increasingly important. With the rise of digital technology, there are now numerous apps available to help individuals monitor and improve their well-being.May 9, 2023 · Biolife Solutions will release earnings for Q1 on May 10. Wall Street predict expect Biolife Solutions will release losses per share of $0.213. Go here to watch Biolife Solutions stock price in ... ... Stock, $0.001 par value of BioLife Solutions, Inc. shall be filed on behalf of the undersigned. November 27, 2020. (Date). Casdin Capital, LLC. By: /s/ Eli ...Discover more Overcome the challenges of cell expansion and product preservation throughout CGT processing. Independent research demonstrates the medium and material used in sample cryopreservation impacts biologic viability. Formulation must be sterile, free from adventitious agents and qualified before use to remove susceptibility from batch-to …CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...
The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.
Nov 27, 2023 · BioLife Solutions Stock Performance. BLFS stock opened at $14.08 on Monday. The business has a 50 day moving average of $12.13 and a 200-day moving average of $16.47. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $26.89. The firm has a market cap of $619.96 million, a PE ratio of -5.94 and a beta of 1.57.
Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...BLFS: Raising target price to $11.00BIOLIFE SOLUTIONS INC has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of Low; a Management …Dec 1, 2023 · BioLife Solutions, Inc. (BLFS) Stock Price, Quote, News & Analysis BLFS BioLife Solutions, Inc. Stock Price & Overview 5.43K followers $10.95 -0.44 ( -3.86%) 4:00 PM 11/10/23 NASDAQ... Stock Price. $10.2. 2023-11-01. Market Capitalization. $457.1 M. 2023-11-01. Revenue. $161.8 M. FY, 2022. BioLife Solutions Summary. Company Summary. Overview. Bothell, WA-based BioLife Solutions, Inc. is a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ...BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ...Mar 22, 2021 · BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ... On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...BOTHELL, Wash., March 22, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the signing of a definitive merger agreement to acquire Global Cooling, Inc., operating as …BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended ...
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BioLife Solutions is introducing initial 2023 revenue guidance, which is based on expectations for its existing business. Expected growth rates are all based on preliminary unaudited revenue. Total revenue for 2023 is expected to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%. Excluding COVID related ...7 dic 2020 ... Thomas Girschweiler sold 1600000 shares, an approximate value of $36 million, of the BioLife Solutions' stock to Casdin Capital LLC.Instagram:https://instagram. florida draftkingsroudntablecapitalize 401k rollover reviewbest places to retire in nevada BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BioLife Solutions, Inc. : News, information and stories for BioLife Solutions, Inc. | Other OTC: | Other OTC valley nat bankasml stoc With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Jan 6, 2023 · While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ... how to invest in artwork BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and ...BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC. Oct. 18. CI. Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating. Aug. 09. MT. Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023. Aug. 08.CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...